Patents by Inventor Steven Rust

Steven Rust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS
    Publication number: 20220195037
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 23, 2022
    Inventors: Elaine M. HURT, Ralph MINTER, Steven RUST, Alan SANDERCOCK, Sotirios KARATHANASIS
  • COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES
    Publication number: 20220177554
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: November 15, 2021
    Publication date: June 9, 2022
    Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha S. CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
  • Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv
    Patent number: 11203633
    Abstract: This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind to Pseudomonas PcrV as well as vectors and host cells comprising the same.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: December 21, 2021
    Assignee: MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha S. Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Compositions and methods for inhibiting cancer stem cells
    Patent number: 11192948
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 7, 2021
    Assignee: MedImmune Limited
    Inventors: Elaine M. Hurt, Ralph Minter, Steven Rust, Alan Sandercock, Sotirios Karathanasis
  • ANTI-PSEUDOMONAS PSL BINDING MOLECULES AND USES THEREOF
    Publication number: 20210130442
    Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: October 19, 2020
    Publication date: May 6, 2021
    Inventors: Antonio DIGIANDOMENICO, Paul G. WARRENER, Charles K. STOVER, Bret SELLMAN, Sandrine GUILLARD, Ralph MINTER, Steven RUST, Mladen TOMICH
  • Anti-Psl binding molecules and uses thereof
    Patent number: 10844114
    Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: November 24, 2020
    Assignee: MedImmune Limited
    Inventors: Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES
    Publication number: 20200317757
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 8, 2020
    Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha S. CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
  • Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
    Patent number: 10597439
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: March 24, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Anti-Pseudomonas PSL Binding Molecules and Uses Thereof
    Publication number: 20190322726
    Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: May 1, 2019
    Publication date: October 24, 2019
    Inventors: Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Anti-pseudomonas Psl binding molecules and uses thereof
    Patent number: 10370436
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 6, 2019
    Assignee: MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS
    Publication number: 20180273616
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 27, 2018
    Inventors: Elaine M. HURT, Ralph MINTER, Steven RUST, Alan SANDERCOCK, Sotirios KARATHANASIS
  • CTLA-4 Variants
    Publication number: 20180208639
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 26, 2018
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • CTLA-4 variants
    Patent number: 9884902
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 6, 2018
    Assignee: MedImmune Limited
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • MULTI-SPECIFIC ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES AND USES THEREOF
    Publication number: 20170183397
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV bispecific binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: May 4, 2015
    Publication date: June 29, 2017
    Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
  • MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF
    Publication number: 20170114151
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Application
    Filed: August 8, 2016
    Publication date: April 27, 2017
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Multispecific and multivalent binding proteins and uses thereof
    Patent number: 9580509
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: February 28, 2017
    Assignee: MedImmune, LLC
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • ANTI-PSEUDOMONAS PSL BINDING MOLECULES AND USES THEREOF
    Publication number: 20160297872
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: June 24, 2016
    Publication date: October 13, 2016
    Inventors: Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Anti-pseudomonas Psl binding molecules and uses thereof
    Patent number: 9403901
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 2, 2016
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES
    Publication number: 20150284450
    Abstract: The disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: November 6, 2013
    Publication date: October 8, 2015
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao
  • CTLA-4 Variants
    Publication number: 20150104450
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev